Comparable stake leader
BAKER BROS. ADVISORS LP
SEC ownership of ACADIA PHARMACEUTICALS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001070494.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ACAD on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BAKER BROS. ADVISORS LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BAKER BROS. ADVISORS LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001070494
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ACADIA PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAKER BROS. ADVISORS LP
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 25%
13D/G row: BAKER BROS. ADVISORS LP
Showing 1-8 of 50 holder rows.
Quick read
BAKER BROS. ADVISORS LP leads the comparable SEC ownership view at 25%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAKER BROS. ADVISORS LP's linked filing trail.
Comparable ownership
Top 5
BAKER BROS. ADVISORS LP
25%
BlackRock, Inc.
12%
STATE STREET CORP
5.3%
VANGUARD PORTFOLIO MANAGEMENT LLC
5.2%
RTW INVESTMENTS, LP
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13D/G
3/4/5
13F
Julian C. Baker · Director, 10%+ Owner · Company
|
25%
|
$1,162,886,859
43,294,373 shares
|
$0 | 24 Feb 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
12%
from 13D/G
|
$479,723,502
21,550,921 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
5.3%
|
$229,628,164
9,076,212 shares
|
$0 | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
5.2%
|
$195,465,216
8,781,007 shares
|
$0 | 31 Mar 2026 |
| RTW INVESTMENTS, LP |
13F
13D/G
Company
|
4.2%
from 13D/G
|
$159,037,104
7,144,524 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.3%
|
$126,022,764
5,661,400 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2%
|
$77,137,406
3,464,689 shares
|
— | 31 Mar 2026 |
| FIRST TRUST ADVISORS LP |
13F
Company
|
2%
|
$74,434,501
3,343,868 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$3,492,291.
Buys
$0
Insiders: 0
Sells
$3,492,291
Insiders: 7
Net
-$3,492,291
Shares: -148,598
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 148,598
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 33,380 | $0 | $844,968 | -$844,968 |
| 3-6 | 0 | 43,774 | $0 | $958,160 | -$958,160 |
| 6-9 | 0 | 44,346 | $0 | $1,010,851 | -$1,010,851 |
| 9-12 | 0 | 27,098 | $0 | $678,312 | -$678,312 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to ACADIA PHARMACEUTICALS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
BAKER BROS. ADVISORS LP
Net 12M change
-$3,492,291
Latest report
29 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director, 10%+ Owner | $878,990,925 | Mixed | 29 May 2026 | ||
| Julian C. Baker | Director, 10%+ Owner | $878,990,925 | Mixed | 29 May 2026 | ||
| Felix Baker | Director, 10%+ Owner | $878,990,925 | Mixed | 29 May 2026 | ||
| Baker Brothers Life Sciences LP | Director, 10%+ Owner | $878,990,925 | Mixed | 29 May 2026 | ||
| Baker Bros. Advisors (GP) LLC | Director, 10%+ Owner | $878,990,925 | Mixed | 29 May 2026 | ||
| 667, L.P. | Director, 10%+ Owner | $878,990,925 | Mixed | 29 May 2026 | ||
| Stephen Davis | CEO, Director | $4,050,942 | Mixed | 16 Aug 2024 | ||
| Adams Catherine Owen | Chief Executive Officer, Director | $2,032,151 | -$249,932 | -11% | Mixed | 24 Mar 2026 |
| Srdjan R. Stankovic | President | $1,834,571 | Mixed | 19 Nov 2022 | ||
| Mark C. Schneyer | Evp, Chief Financial Officer | $1,519,489 | -$1,175,537 | -44% | Mixed | 01 May 2026 |
| Douglas J. Williamson | Executive VP, Research & Dev | $1,517,624 | Mixed | 10 Feb 2023 | ||
| Austin D. Kim | EVP,General Counsel, Secretary | $1,405,154 | Filing P/S | 06 Jan 2024 | ||
| Brendan Teehan | Evp, Coo, Head Of Commercial | $1,210,623 | Mixed | 17 Nov 2024 | ||
| Edmund Harrigan | Director | $1,119,490 | Mixed | 29 May 2026 | ||
| Elizabeth H.z. Thompson | EVP, Head of Research & Dev | $986,748 | -$506,412 | -34% | Mixed | 29 Jul 2026 |
| Daniel B. Soland | Director | $927,091 | Mixed | 29 May 2025 | ||
| Elizabeth A. Garofalo | Director | $904,481 | -$41,560 | -4.4% | Mixed | 29 May 2026 |
| Jennifer J. Rhodes | Evp, Chief Legal Officer, Sec | $790,211 | -$245,022 | -24% | Mixed | 24 Mar 2026 |
| Thomas Garner | EVP, Chief Commercial Officer | $762,703 | Mixed | 06 Mar 2026 | ||
| Adora Ndu | Director | $732,532 | Mixed | 29 May 2026 |
Recent insider transactions for ACADIA PHARMACEUTICALS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Elizabeth H.z. Thompson | ACAD | Common Stock | Sale | -46.6% | $432,663 | $26.13 | -16,558 | 18,994 | 30 Jul 2026 | Direct |
| Elizabeth H.z. Thompson | ACAD | Common Stock | Options Exercise | 983.9% | 32,272 | 35,552 | 29 Jul 2026 | Direct | ||
| Elizabeth H.z. Thompson | ACAD | Restricted Stock Units | Options Exercise | -50% | -32,272 | 32,272 | 29 Jul 2026 | Direct | ||
| James Kihara | ACAD | Common Stock | Sale | -46.6% | $297,912 | $26.08 | -11,421 | 13,088 | 26 Jun 2026 | Direct |
| BAKER BROS. ADVISORS LP | ACAD | Common Stock | Award | 0.09% | 37,244 | 39,384,587 | 29 May 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | ACAD | Common Stock | Award | 0.09% | 37,244 | 39,384,587 | 29 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | ACAD | Common Stock | Award | 0.09% | 37,244 | 39,384,587 | 29 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | ACAD | Common Stock | Award | 0.09% | 37,244 | 39,384,587 | 29 May 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | ACAD | Common Stock | Award | 0.09% | 37,244 | 39,384,587 | 29 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | ACAD | Common Stock | Award | 0.09% | 37,244 | 39,384,587 | 29 May 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | ACAD | Non- Qualified Stock Option (right to buy) | Award | 64,016 | 32,008 | 29 May 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | ACAD | Non- Qualified Stock Option (right to buy) | Award | 64,016 | 32,008 | 29 May 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | ACAD | Non- Qualified Stock Option (right to buy) | Award | 64,016 | 32,008 | 29 May 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | ACAD | Non- Qualified Stock Option (right to buy) | Award | 64,016 | 32,008 | 29 May 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | ACAD | Non- Qualified Stock Option (right to buy) | Award | 64,016 | 32,008 | 29 May 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | ACAD | Non- Qualified Stock Option (right to buy) | Award | 64,016 | 32,008 | 29 May 2026 | See Footnotes | |||
| Edmund Harrigan | ACAD | Common Stock | Options Exercise | 23.1% | 8,107 | 43,148 | 29 May 2026 | Direct | ||
| Edmund Harrigan | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| Edmund Harrigan | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| Edmund Harrigan | ACAD | Restricted Stock Units | Options Exercise | -100% | -8,107 | 0 | 29 May 2026 | Direct | ||
| Laura Brege | ACAD | Common Stock | Options Exercise | 53.7% | 8,107 | 23,202 | 29 May 2026 | Direct | ||
| Laura Brege | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| Laura Brege | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| Laura Brege | ACAD | Restricted Stock Units | Options Exercise | -100% | -8,107 | 0 | 29 May 2026 | Direct | ||
| Adora Ndu | ACAD | Common Stock | Options Exercise | 32.7% | 8,107 | 32,908 | 29 May 2026 | Direct | ||
| Adora Ndu | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| Adora Ndu | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| Adora Ndu | ACAD | Restricted Stock Units | Options Exercise | -100% | -8,107 | 0 | 29 May 2026 | Direct | ||
| Elizabeth A. Garofalo | ACAD | Common Stock | Options Exercise | 31.9% | 8,107 | 33,489 | 29 May 2026 | Direct | ||
| Jonathan Poole | ACAD | Common Stock | Options Exercise | 2,010 | 2,010 | 29 May 2026 | Direct | |||
| Jonathan Poole | ACAD | Common Stock | Options Exercise | 2,010 | 2,010 | 29 May 2026 | Direct | |||
| Elizabeth A. Garofalo | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| Elizabeth A. Garofalo | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| Elizabeth A. Garofalo | ACAD | Restricted Stock Units | Options Exercise | -100% | -8,107 | 0 | 29 May 2026 | Direct | ||
| Jonathan Poole | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| Jonathan Poole | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| Jonathan Poole | ACAD | Restricted Stock Units | Options Exercise | -100% | -2,010 | 0 | 29 May 2026 | Direct | ||
| Jonathan Poole | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| Jonathan Poole | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| Jonathan Poole | ACAD | Restricted Stock Units | Options Exercise | -100% | -2,010 | 0 | 29 May 2026 | Direct | ||
| James M. Daly | ACAD | Common Stock | Options Exercise | 200.6% | 8,107 | 12,148 | 29 May 2026 | Direct | ||
| James M. Daly | ACAD | Restricted Stock Units | Award | 9,311 | 9,311 | 29 May 2026 | Direct | |||
| James M. Daly | ACAD | Director Stock Options (Right to Buy) | Award | 16,004 | 16,004 | 29 May 2026 | Direct | |||
| James M. Daly | ACAD | Restricted Stock Units | Options Exercise | -100% | -8,107 | 0 | 29 May 2026 | Direct | ||
| James Kihara | ACAD | Common Stock | Sale | -18.1% | $114,393 | $21.18 | -5,401 | 24,509 | 26 May 2026 | Direct |
| James Kihara | ACAD | Common Stock | Sale | -4.37% | $29,024 | $21.79 | -1,332 | 29,129 | 04 May 2026 | Direct |
| Mark C. Schneyer | ACAD | Common Stock | Sale | -5.03% | $76,396 | $21.79 | -3,506 | 66,145 | 04 May 2026 | Direct |
| James Kihara | ACAD | Common Stock | Options Exercise | 9.32% | 2,596 | 30,461 | 01 May 2026 | Direct | ||
| James Kihara | ACAD | Restricted Stock Units | Options Exercise | -50% | -2,596 | 2,596 | 01 May 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Common Stock | Options Exercise | 10.8% | 6,815 | 69,651 | 01 May 2026 | Direct |
* marks a reported price that did not pass the local price check.